The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours
- Author(s)
- Foo, T; Goldstein, D; Segelov, E; Shapiro, J; Pavlakis, N; Desai, J; Yip, D; Zalcberg, J; Price, TJ; Nagrial, A; Chantrill, L; Burge, M; Karapetis, CS; Tebbutt, N; Roy, AC;
- Details
- Publication Year 2022-03,Volume 17,Issue #2,Page 95-110
- Journal Title
- Targeted Oncology
- Publication Type
- Research article
- Abstract
- Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal tract mesenchymal tumours. Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced GIST. Imatinib was the first TKI to gain approval as management for patients with advanced GIST, establishing a new standard of care. Since then, as a result of several trials including the GRID and INVICTUS studies, we now have five lines of approved targeted therapy, including imatinib, sunitinib, regorafenib, ripretinib and avapritinib for the treatment of unresectable, advanced GISTs. In this review, the Australasian Gastrointestinal Trials Group (AGITG) provide an overview of the key trials that have changed clinical practice, discuss the molecular drivers of GISTs, the importance of molecular testing and directing therapy according to molecular targets, as well as future strategies in the management of advanced GISTs.
- Keywords
- *Antineoplastic Agents/pharmacology/therapeutic use; *Gastrointestinal Neoplasms/drug therapy/pathology; *Gastrointestinal Stromal Tumors/drug therapy; Humans; Imatinib Mesylate/pharmacology/therapeutic use; Protein Kinase Inhibitors/therapeutic use; Sunitinib/therapeutic use
- Department(s)
- Medical Oncology
- PubMed ID
- 35290591
- Publisher's Version
- https://doi.org/10.1007/s11523-022-00869-y
- Open Access at Publisher's Site
https://doi.org/10.1007/s11523-022-00869-y- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-10-25 06:46:32
Last Modified: 2024-10-25 06:48:14